Supply Chain entity
Every one of those 1 sits in a single category, regulation. UBS is most often covered alongside Active Pharmaceutical Ingredients (APIs), which appears in 1 of these 1 story. Their average consequence score of 8 runs above the beat's 6.6 for that window.
Last mentioned: 6d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. UBS is most often covered alongside Active Pharmaceutical Ingredients (APIs), which appears in 1 of these 1 story. Their average consequence score of 8 runs above the beat's 6.6 for that window. Source depth averages 3 original sources per story, versus 2.6 across the same-window beat baseline. UBS appears in 1 tracked Supply Chain story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 36 Supply Chain stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UBS. Shared-story counts are live from our verified record — not editorial picks.
US lawmakers are raising alarms over the pharmaceutical industry's reliance on Chinese ingredients, warning that Beijing is applying its 'rare earths playbook' to dominate global medicine. A House Select Committee hearing highlighted concerns that China's control over active pharmaceutical ingredients and the biotech pipeline poses a strategic threat to American healthcare security.
UBS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
